Insulin resistance and the sympathetic nervous system

Current Hypertension Reports

Volumn 5, Issue 3, 2003, Pages 247-254

  Egan, Brent M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CATECHOLAMINE; CYTOKINE; ENDORPHIN; FATTY ACID; ICOSANOID; INSULIN; LEPTIN; LIOTHYRONINE; NEUROPEPTIDE Y; NITRIC OXIDE; NORADRENALIN;

ADRENERGIC SYSTEM; ARTERY COMPLIANCE; CARDIOVASCULAR RISK; CATECHOLAMINE BLOOD LEVEL; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; NORADRENALIN BLOOD LEVEL; OBESITY; PATHOGENESIS; PRESSORECEPTOR REFLEX; REVIEW; RISK FACTOR; SLEEP APNEA SYNDROME; SUDDEN DEATH; TACHYCARDIA; VASCULAR ENDOTHELIUM; VASODILATATION; BLOOD; CARDIOVASCULAR DISEASE; INNERVATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

CARDIOVASCULAR DISEASES; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LEPTIN; METABOLIC SYNDROME X; MUSCLE, SKELETAL; OBESITY; RISK FACTORS; SLEEP APNEA SYNDROMES; SYMPATHETIC NERVOUS SYSTEM;

EID: 0141799755     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0028-7     Document Type: Review

References (91)

1. Ferrannini E, Natali A, Bell P, et al.: Insulin resistance and hypersecretion in obesity. J Clin Invest 1997, 100:1166-1173.
2. Bunker CH, Ukoli FA, Matthews KA, et al.: Weight threshold and blood pressure in a lean black population. Hypertension 1995, 26:616-623.
3. Lipton RB, Liao Y, Cao G, et al.: Determinants of incident non-insulin-dependent diabetes mellitus among blacks and whites in a national sample. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1993, 138:826-839.
4. Prebble WE: Obesity:observations on one thousand cases. Boston Med Surg J 1923, 88:617-621.
5. Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
6. Kannel WB, Wilson PW, Nam BH, D'Agostino RB: Risk stratification of obesity as a coronary risk factor. Am J Cardiol 2002, 90:697-701.
7. Hubert HB, Feinleib M, McNamara PM, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983, 67:968-977.
8. Messerli FH, Nunez BD, Ventura HO, Snyder DW: Overweight and sudden death: Increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med 1987, 147:1725-1728.
9. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-20. JAMA 2002, 288:1723-1727.
10. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
11. Obesity: preventing and managing the global epidemic. In Report of a WHO Consultation on Obesity. Geneva: World Health Organization, 1998.
12. Lakka H-M, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
13. Wolf AM, Colditz GA: Current estimates of the economic cost of obesity in the United States. Obes Res 1998, 6:97-106.
14. Sturm R: The effects of obesity, smoking, and drinking on medical problems and costs. Obesity outranksboth smoking and drinking in itsdeleterious effects on health and health cost. Health Affairs 2002, 21:245-253.
15. Quesenberry CP, Caan B, Jacabson A: Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998, 158:466-472.
16. Field AE, Coakley EH, Must A, et al.: Impact of overweight on the risk of developing common chronic disease during a 10-year period. Arch Intern Med 2001, 161:1581-1586.
17. National Task Force on the Prevention and Treatment of Obesity: Weight cycling. JAMA 1994, 272:1196-1202.
18. Snitker S, Macdonald I, Ravussin E, Astrupp A: The sympathetic nervous system and obesity: the role in aetiology and treatment. Obes Rev 2000, 1:5-15.
19. Esler M, Magdalen R, Weisner G, et al.: Sympatheric nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 2001, 14:304S-309S.
20. Grassi G, Seravalle G, Dell-Oro R, et al.: Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 200, 36:538-542.
21. Egan B, Panis R, Hinderliter A, et al.: Mechanism of increased a-adrenergic vasoconstruction in human essential hypertension. J Clin Invest 1987, 80:812.817.
22. Quillot D, Fluckiger L, Zannad F, et al.: Impaired autonomic control of heart rate and blood pressure in obesity: role of age and of insulin-resistance. Clin Autonom Res 2001, 11:79-86.
23. Gao YY, Lovejoy, Spart An, et al.: Autonomic activity assessed by heart rate spectral analysis varies with fat distribution in obese women. Obes Res 1996, 4:55-63.
24. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415-420.
25. Jamerson KA, Julius S, Gudbrandson T, et al.: Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993, 21:618-623.
26. Rocchini AP, Mao HZ, Babu K, et al.: Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension 1999, 33(part 2):548-553.
27. Hall JE, Brands MW, Hilderbrandt DA, et al.: Role of sympathetic nervous system and neuropeptides in obesity hypertension. Brazil J Med Biol Res 2000, 33:605-618.
28. Wofford MR, Anderson DC, Brown CA, et al.: Antihypertensive -effect of a- and b-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001, 14:694-698.
29. Sower JR, Nyby M, Stern N, et al.: Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension 1982, 4:686-691.
30. Esler M, Zweifler A, Randall O, et al.: The determinants of plasma-renin activity in essential hypertension. Ann Intern Med 1978, 88:746-752.
31. Egan BM, Stepniakowski K, Goodfriend TL: Renin and aldosterone are higher and the hyperinsulinemic effects of salt restriction greater in subjects with risk factor clustering. Am J Hypertens 1994, 7:886-893.
32. Rothwell NJ: Central regulation of thermogenesis. Crit Rev Neurobiol 1994, 8:1-10.
33. Carroll JF, Hunag M, Hester RL, et al.: Hemodynamic alterations in hypertensive obese rabbits. Hypertension 1995, 26:465-470.
34. Mark AL, Correia M, Morgan DA, et al.: State-of-the-art lecture: Obesity-induced hypertension: New concepts from the emerging biology of obesity. Hypertension 1999, 33(part 2):537-541.
35. Hwang I-S, Ho H, Hoffman BB, Reaven GM: Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987, 10:512-516.
36. Tuck ML: Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 1992, 19(Suppl 1):I67-I77.
37. Rocchini AP, Key J, Bondie D, et al.: The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989, 321:580-585.
38. Esler M, Ferrier C, Lambert G, et al.: Biochemical evidence of sympathetic hyperactivity in human hypertension. Hypertension 1991, 17(Suppl III):III29-III35.
39. Guyton AC: Blood pressure control - special role of the kidneys and body fluids. Science 1991, 252:1813-1816.
40. Grassi G, Seravalle G, Dell'Oro R, et al.: Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 200, 36:538-542.
41. Grassi G, Seravalle G, Colombo M, et al.: Body weight reduction, sympathetic nerve activity, and arterial baroreflex in obese normotensive humans. Circulation 1998, 97:2037-2042.
42. Laakso M, Edelman SV, Bretchel G, Baron AD: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. J Clin Invest 1990, 85:1844-1852.
43. Andersson B, Elam M, Wallin BG, etal.: Effect of energy-restricted diet on sympathetic muscle nerve activity in obese women. Hypertension 1991, 18:783-789.
44. Jones PP, Snitker S, Skinner JS, Ravussin E: Gender differences in muscle sympathetic nerve activity: effect of body fat distribution. Am J Physiol 1996, 270:E363-E366.
45. Kissebah AH, Krakower GR: Regional adiposity and morbidity. Physiol Rev 1994, 74:761-811.
46. Stern M, Haffner S: Body fat distribution and hyperinsulinemia as a risk factors for diabetes and cardiovascular disease. Arteriosclerosis 1986, 6:123-129.
47. Heitmann BL: Body fat distribution in the adult Danish population aged 35 - 65 years: an epidemiological study. Int J Obes 1991, 58:535-545.
48. MacMahon SW, Blacket RB, Macdonald GJ, Hall W: Obesity, alcohol consumption and blood pressure in Australian men and women. The National Heart Foundation of Australia Risk factor Prevalence Study. J Hypertens 1984,2:85-91.
49. Emdin M, Gastaldelli A, Muscelli E, et al.: Hyperinsulinemia and autonomic nervous system dysfunction in obesity: Effects of weight loss. Circulation 2001, 103:513-519.
50. Hirsch J, Leibel RL, Mackintosh R, Aguirre A: Heart rate variability as a measure of autonomic function during weight change in humans. Am J Physiol 1991, 261:R1418-R1423.
51. Hausberg M, Hoffman RP, Somers VK, et al.: Contrasting autonomic and hemodynamic effects of insulin in health elderly versus young subjects. Hypertension 1997, 29:700-705.
52. Anderson EA, Balon TW, Hoffman RP, et al.: Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension 1992, 19:621-627.
53. Wollenweider P, Tappy L, Randin D, et al.: Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest 1993, 92:147-154.
54. Monroe MB, Van Pelt RE, Schiller BC, etal.: Relation of leptin and inslin to adiposity-associated elevations in sympathetic activity with age in humans. Int J Obes 2000, 24:1183-1187.
55. Jensen MD, Haymond MW, Rizza RA, et al.: Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989, 83:1168-1173.
56. Reaven GM, Hollenbeck C, Jeng CY, et al.: Measurement of plasma glucose, free fatty acids, lactate, and insulin for 24 hours in patients with NIDDM. Diabetes 1988, 37:1020-1024.
57. Ferrannini E, Barrett EJ, Bevilacqua S: Effects of fatty acids on glucose production and utilization in man. J Clin Invest 1983, 72:1737-1747.
58. Cabezas MC, deBruin TWA, deValk HW, et al.: Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating apolipoprotien B overproduction and insulin resistance. J Clin Invest 1993, 92:160-168.
59. Bülow J, Madsen J, Hojgaard L: Reversibility of the effects on local circulation of high lipid concentrations in blood. Scand J Clin Lab Invest 1990, 50:291-296.
60. Grekin RJ, Dumont CJ, Vollmer AP, et al.: Mechanism in the pressor effects of hepatic portal venous fatty acid infusion. Am J Physiol 1997, 273:R324-R330.
61. Hilderbrandt DA, Kirk D, Hall JE: Renal and cardiovascular responses to chronic increases in cerebrosvascular free fatty acids. Fed Proc 1999, 13:780.
62. Stojiljkovic MP, Zhang D, Lopes HF, et al.: Hemodynamics effects of lipids in humans. Am J Physiol 2001, R280:1674-1679.
63. Steinberg HO, Tarshoby M, Monestel R, et al.: Elevated circulating free fatty acid levels impair endothelium-dependent vasolidation. J Clin Invest 1997, 100:1230-1239.
64. Haastrup T, Stepniakowski KT, Goodfriend TL, Egan BM: Lipids enhance a1-adrenergic receptor mediated pressor reactivity. Hypertension 1998, 32:693-698.
65. Thomas GD, Sander M, Lau KS, et al.: Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci U S A 1998, 95:15090-15095.
66. Fagot-Campagna A, Balkau B, Simon D, et al.: High free fatty acid concentration: An independent risk factor for hypertension in the Paris Prospective Study. Int J Epidemiol 1998, 27:808-813.
67. Gadegbeku CA, Dhandayuthapani A, Sadler JE, Egan BM: Raising lipids acutely reduces baroreflex sensitivity. Am J Hypertens 2002, 15:479-485.
68. Paolisso G, Manzella D, Rosaria MR, et al.: Elevated plasma fatty acid concentrations stimulate the cardiac autonomic nervous system in healthy subjects. Am J Clin Nutr 2000, 72:723-730.
69. Jouven X, Charles M-A, Desnos M, Ducimetière P: Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 2001, 104:756-761.
70. Chan JC, Cheung JC, Stehouwer CD, et al.: The central roles of obesity-associated dyslipidaemia, endothlelial activation and cytokines in the metabolic syndrome - an analysis by structural equation modeling. Int J Obes 2002, 26:994-1008.
71. Maguri SR, Hauser R, Schwartz J, et al.: Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation 2001, 104:986-991.
72. Vgontzas AN, Papanicolaou DA, Bixler EO, et al.: Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000, 85:1151-1158.
73. O'Dea K, Esler M, Leonard P, et al.: Noradrenaline turnover during under-and over-eating in normal weight subjects. Metabolism 1982, 31:896-899.
74. Engeli S, Sharma AM: Role of adipose tissue for cardiovascular-renal regulation in health and disease. Horm Metab Res 2000, 21:485-499.
75. Brody MJ, Kadowitz PJ: Prostaglandins as modulators of autonomic nervous system. Fed Proc 1974, 33:48-60.
76. Stjärne L: Enhancement by indomethacin of cold-induced hypersecretion of noradrenaline in the rat in vivo by suppression of PGE mediated feedback control? Acta Physiol Scand 1972, 86:388-397.
77. Quadri F, Carretero OA, Scicli AG: Centrally produced nitric oxide in the control of baroreceptor reflex sensitivity and blood pressure in normotensive and hypertensive spontaneously hypertensive rats. Jpn J Pharmacol 1999, 81:279-285.
78. Tanioka H, Nakamura K, Fujimura S, et al.: Facilitatory role of NO in neural norepinephrine release in the rat kidney. Am J Physiol 2002, 282:R1436-R1442.
79. Kou JJ, Jones OB, Hall JE: Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001, 37(part 2):670-676.
80. Konishi S, Tsunoo A, Otsuka M: Enkephalins presynaptically inhibit cholinergic transmission in sympathetic ganglia. Nature 1979, 282:515-516.
81. Paquali R, Cantobelli S, Casimirri F, et al.: The role of opioid peptides in the development of hyperinsulinemia in obese women with abdominal fat distribution. Metabolism 1992, 41:763-767.
82. McCubbin JA, Survit RS, Williams RB, et al.: Altered pituitary hormone response to naloxone in hypertension development. Hypertension 1989, 14:636-644.
83. Ramirez-Gonzalez MD, Tchakarov L, Garcia RM, Kunos G: b-endorphin acting on the brainstem is involved in the antihypertensive action of clonidine and a-methyldopa in rats. Circ Res 1983, 53:150-157.
84. Bouloux P-M, Grossman A, Al-Damluji S, et al.: Enhancement of the sympathoadrenal response to the cold-pressor test by naloxone in man. Clin Sci 1985, 69:365-368.
85. Rothman RB, Xu H, Char GU, et al.: Phenylpiperidine opioid antagonists that promote weight loss in rats have high affinity for the k2b (enkephalin-sensitive) binding site. Peptides 1993, 14:17-20.
86. Balasubramaniam A: Clinical potential of neuropeptide Y family of hormones. Am J Surg 2002, 183:430-434.
87. Silverberg DS, Oksenberg A: Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? Curr Hypertens Rep 2001, 3:209-215.
88. Roux F, D'Ambrosio C, Mohsenin V: Sleep-related breathing disorders and cardiovascular disease. AM J Med 2000, 108:396-402.
89. Fletcher EC, Lesske J, Behm R, et al.: Carotid chemoreceptors, systemic blood pressure, and chronic episodic hypoxia mimicking sleep apnea. J Appl Physiol 1992, 72:1978-1984.
90. Ries DJ, Morrison S, Ruggiero DA: The C1 area of the brainstem in tonic and reflex control of blood pressure: state of the art lecture. Hypertension 1988, 11(Suppl 1):I8-I13.
91. Johnson EH: Interrelationship between psychological factors, overweight, and blood pressure in adolescents. J Adolesc Health Care 1990, 11:310-318.